Trinity Delta Lighthouse: Scancell
Trinity Delta view: Scancell’s investment case centres on the potential of the lead oncology programmes from its highly promising ImmunoBody and Moditope “off the shelf” platforms. iSCIB1+ already forms the majority of our current rNPV (51.3%) and this is set to rise as Scancell navigates key de-risking events such as securing the funding for iSCIB1+ to enter this pivotal Phase III study. The quality and duration of responses seen in SCOPE provide reassurance that iSCIB1+ could alter standard of care in advanced melanoma if replicated in the registrational trial. Investor attention will now focus on the likely funding mechanism for the trial, with partnership expected to be one of the principal avenues under consideration. Our rNPV valuation is £382m, or 37p/share, with further upside potential as iSCIB1+ progresses and the expected news flow from both the Moditope platform (Phase I/II ModiFY data from the renal cell carcinoma cohort exploring Modi-1 with doublet CPIs) and the GlyMab portfolio.Scancell Holdings is engaged in the discovery and development of novel vaccines for the treatment of cancer based on its proprietary immuno-oncology platforms, ImmunoBody®, and Moditope®. Co.'s ImmunoBody® consist of SCIB1 melanoma vaccine, and SCIB2 lung cancer vaccine. Co. has a collaboration partnership to evaluate the use of its SCIB2 to treat non-small cell lung cancer. Co.'s Moditope® technology is a vaccine platform that targets neo-epitopes to overcome immune suppression induced by tumour cells. Co.'s Moditope® product, Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide for the treatment of breast cancer, ovarian cancer and sarcoma.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.